Introduction {#S1}
============

In all endemic areas the risk, frequency and severity of malaria infection are greater in pregnant women than in the same women before pregnancy or in their non-pregnant counterparts. Regardless of the pre-pregnancy level of immunity against malaria, clinical consequences of pregnancy-associated malaria include maternal anemia, low newborn birth weight (LBW), pre-term delivery, and increased prenatal morbidity.^[@R1]^

Prevention of malaria in pregnancy remains a major public health challenge and a priority for the Roll Back Malaria (RBM) Partnership. Methods of malaria prevention in pregnancy changed from a weekly or bimonthly chemoprophylaxis to intermittent preventive treatment (IPTp) and insecticide-treated bed nets (ITNs) at the beginning of the 21^st^ centrury.^[@R2]^ Sulfadoxine-pyrimethamine (SP) is the drug currently recommended for IPTp strategy.^[@R2]^ It has a good safety profile and remains a good option in endemic areas of Africa.^[@R3]^ IPTp-SP is used to treat pregnant women, regardless of their malaria infection status, with spaced therapeutic doses (2--3 doses) during the second and third trimesters of pregnancy .^[@R4]^

Nigeria adopted the IPTp strategy in 2005 and the current National Malaria Treatment Guideline and Policy in Nigeria recommends SP as the drug of choice for IPTp and quinine for treatment of clinical malaria in all trimesters. Artemisinin based combination therapy (ACT) is considered a safe second-line agent in the second and third trimesters and may be used in the first trimester in cases in which there are no suitable alternatives.^[@R5]^ IPTp-SP has been shown to reduce the risk of maternal anemia, placental parasitemia and low birth weight.^[@R6],[@R7]^ The ongoing use of SP, either in treatment of uncomplicated malaria or as a method of malaria control by intermittent preventive treatment, makes it important to constantly study SP resistance and the way resistance spreads in populations. The resistance against the pyrimethamine component of the SP combination occurs due to multiple key mutations in the dihydrofolate reductase (dhfr) gene of the parasite. The first mutation to appear is serine to asparagine at codon *108* of the dhfr (S108N), followed by asparagine to isoleucine at codon *51* (N51I) and cysteine to arginine at codon *59* (C59R), leading to triple mutation-108N + 51I + 59R.^[@R8]^ The mutations in the dihydropteroate synthase (dhps) gene at codons 436, 437, 540 and 581 are associated with resistance to sulfadoxine.^[@R8],[@R9]^ Additional mutation at the dhfr codon *164*, which is isoleucine to leucine (I164L), provides high-level resistance against pyrimethamine, mostly found in the parasites in Southeast Asia^[@R10]^ and Latin America.^[@R11]^ However, few studies report the emergence of the I164L mutation in East Africa.^[@R12],[@R13]^ The main aim of the present study, therefore, is to assess the prevalence of dhfr mutation in asymptomatic and submicroscopic *P. falciparum* isolates from pregnant women in Nigeria and to explore the possible association of such infection.

Materials and Methods {#S2}
=====================

Study area
----------

The study was carried out in Ilorin, the capital city of Kwara State, located in the middle belt region of Nigeria (lat. 8 30°N, long. 4 30°E) and has a Guinea Savannah type of vegetation. Average daily temperature is 37°C, with a minimum mean temperature of 20°C and maximum mean temperature of 39°C. Average rainfall is about 1,270 mm which falls almost entirely during the wet season from April to October. Patient recruitment took place at the maternity unit of the University of Ilorin Teaching Hospital (UITH), a tertiary health institution that functions as a teaching hospital.

Study population and recruitment
--------------------------------

Pregnant women attending the antenatal clinic participated in the study. Apparently healthy pregnant women were adequately briefed about the purpose and benefits of this study and their consent was obtained before recruitment. Approval for the study was obtained from the UITH ethical committee.

Sample collection and processing
--------------------------------

Finger prick blood sample was collected from each subject for thick and thin blood smears, which were Giemsa stained and checked for *P. falciparum* parasites. The level of parasitemia (parasites/mL blood) was estimated from the results of a leukocyte count and a count of malarial parasites against 200 leukocytes in the thick smear. Two drops of blood were also blotted onto 3 MM Whatman filter paper for molecular studies. All subjects found to be infected were referred to a physician and treated with appropriate artemisinin combination therapy.

Hemoglobin estimation was carried out using photoelectric colorimeter according to Sahli\'s method, as previously described.^[@R14]^ Severe anemia was indicated by an Hb concentration of 7.0 g/dL and mild-moderate anemia by an Hb concentration of 7.0--10.5 g/dL The Hb concentration used as the threshold for anemia was thus reduced from the usual 11.0 g/dL to 10.5 g/dL, to allow for the hemodilution that occurs during pregnancy.^[@R15]^ The cellulose acetate membrane (CAM) was used to determine the genotype of each patient.^[@R16]^

Detection of sub-microscopic malaria by PCR
-------------------------------------------

DNA was extracted from the dried blood spots on filter paper using the QIAamp®DNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer\'s protocol, and stored at −20°C until further analysis. Stevor gene was used for the detection of submicroscopic malaria as previously described.^[@R17]^ This gene was chosen because it is a multi-copied gene and we have previously reported that it has a 100% sensitivity and specificity.^[@R17]^

Detection of DHFR gene mutation
-------------------------------

The PCR assays for dhfr mutation included a primary and semi-nested reaction to enhance specificity and sequencing was performed to determine the mutations. In the first reaction, 5.0 µL of DNA extract were amplified in a final volume of 25 µL containing 2.5 µL of reaction buffer, 25mM dNTPs, 0.75 units of Taq DNA polymerase, and 0.5µM of forward and reverse primers. In the first reaction, a 654-basepair (bp) portion of the dhfr gene was amplified by primers DhfrFwd (5-TTTATATTTTCTCCTTTTTAT-3) and DhfrRvd (5-ACGCTAACAGA AATAATTTGA TACTC-3). For the second reaction, 3µl of amplified product from the first PCR product was added to the second PCR mixture. Dhfr Fwd2 (5-TAAGGTTGAAAGC AAAAATGAGG-3) and DhfrRvd were used to amplify a 581-bp fragment containing codons *51, 59, 108* and *164*. The primers were designed using the Vector NTI Advance™ version 11.0. PCR products were subjected to electrophoresis on 1.5% agarose gels and visualized by transillumination with ultraviolet light after staining with SYBR® Green. Amplicon sequence was determined using an ABI PRISIM 3100 Genetic Analyser (Applied Biosystem). Sequence results were analyzed using the Vector NTI Advance™ version 11.0 software.

Statistical analysis
--------------------

Statistical analysis was carried out using Graph-pad Instat (Graphpad Software Inc., San Diego, USA). Frequencies were compared using Fisher\'s exact tests and two sided P \< 0.05 were considered statistically significant.

Results {#S3}
=======

A total of 179 pregnant women participated in the study. Their characteristics are shown in [Table 1](#T1){ref-type="table"}. The overall prevalence of women with *P. falciparum* parasitemia determined by PCR was 41.1% (79/179). Gestational age, parity and blood group did not produce any significant effect on the presence of malaria parasitemia in the study population. Similarly, there was no significant difference between the hemoglobin concentrations of those with or without malaria. Anemia was more common among women with malaria parasitemia but the difference was not statistically significant ([Table 1](#T1){ref-type="table"}).

Table 1Characteristics of the pregnant women with and without submicroscopic *P. falciparum* infection in Ilorin, Nigeria.CharacteristicsWith malaria parasite N = 79Without malaria parasite N = 100PMean age ± SD28.3±5.0429.1±5.160.192Gestational age2^nd^ trimester43 (54.4%)64 (64.0%)0.1953^rd^ trimester36 (45.6%)36 (36.0%)ParityPrimigravide36 (46.6%)51 (51.0%)0.470Multigravide43 (54.4%)49 (54.4%)Blood groupA27 (34.2%)45 (45%)AB5 (6.3%)2 (2%)B14 (17.7%)13 (13%)0.221O+32 (40.5%)40 (40%)O−1 (1.3%)0 (0.0%)Mean hemoglobin11.2±1.4611.4± 1.370.347Anemia23 (29.1%)23 (23%)0.354

Out of the 79 positive cases obtained by stevor PCR, 39 isolates were successfully genotyped for the 3 point mutations on the dhfr gene. The frequency of the point mutations and the combination of the mutations are shown in [Table 2](#T2){ref-type="table"}. The prevalence of the mutant *108* alleles was 38.5% and 12.8% for N108 and T108, respectively. For the positions *51* and *59*, the prevalence of mutant alleles was 64.1% (I51) and 61.5% (R59). The prevalence of the triple mutant alleles (N108 + I51 + R59) in the population was 17.9%. The prevalence of the triple mutant alleles with respect to number of doses of SP is compared in [Table 3](#T3){ref-type="table"}. No statistically significant difference was observed between the number of doses and the development of dhfr triple mutation.

Table 2Prevalence of dhfr mutations in *P. falciparum* isolates obtained from pregnant Women in Ilorin, Nigeria.GeneAmino Acid Wild/MutantN = 39 WildMutantMixed*51*N/I10 (25.6%)25 (64.1%)4(10.3%)*59*C/R13 (33.3%)24(61.5%)2 (5.1%)*108*S/N19 (48.7%)15 (38.5%)0S/T5 (12.8%)*164*I/L40 (100%)00*51 + 59*13 (33.3%)26 (66.7%)0*51 + 108*3 (7.7%)10 (25.6%)26 (66.7%)*59 + 108*1 (2.6%)7 (17.9%)31 (79.5%)*51 + 59 + 108*0 (37.5%)7(17.9%)32 (82.1%)

Table 3The effect of number of doses of SP on the presence of triple dhfr mutation.SP DoseN.Dhfr triple mutationP1 dose255 (20%)\> 1 dose142 (14%)1.0000Total397 (17.9%)

Discussion {#S4}
==========

This study shows the prevalence of the dhfr mutations among parasites obtained from pregnant women with asymptomatic malaria after single or double dose(s) of SP used for IPTp in Nigeria. Dhfr resistant alleles have not yet been well correlated to SP effectiveness in pregnant women. We have previously reported a high prevalence of triple mutant dhfr alleles among children with uncomplicated falciparum malaria suggesting that there is a widespread pyrimethamine resistance in Nigeria.^[@R18]^ The high prevalence of triple mutant (17.9%) and N108 mutation (38.5%) of the dhfr alleles observed in asymptomatic *P. falciparum* cases may be an indication that SP has a limited duration of usefulness as IPTp in this part of the country. A change from wild-type S108 to N108 has been shown to be adequate to cause low-level pyrimethamine resistance both *in vitro* and *in vivo*. The addition of other mutations (C50 to R50, N51 to I51, and C59 to R59) yield a higher level of resistant. Also, more recently, the addition of a mutation at codon *164* (I164 to L164) has been shown to confer the highest level of resistance; although this mutation is not common in African isolates.

The emergence of SP-resistant parasites among pregnant women in Nigeria could be explained in part by previous pyrimethamine chemoprophylaxis usage. Weekly dose of pyrimethamine monotherapy was previously commonly used among pregnant women for prevention of malaria in pregnancy in Nigeria^[@R19],[@R20]^ and a recent survey (RL Opatokun, unpublished data, 2011) in Osogbo, South Western Nigeria the country showed that over 10% of pregnant women are still using Daraprim®, a weekly pyrimethamine monotherepy for malaria prevention. Current IPT-Sp treatment and previous pyrimethamine monotherapy in pregnant women could have caused bias by selecting resistant parasites on an individual basis and successively over time. An earlier study in Tanzania showed that pyrimethamine chemoprophylaxis in children was paralleled by a rapid emergence and worsening of drug resistance, arguing against the use of pyrimethamine as a monosubstance.^[@R8]^ In this study, we did not observe a significant difference in the prevalence of triple dhfr mutant alleles between women that took a single dose compared to those who took 2 or 3 doses. One limitation of this study was that the drugs were not taken under the supervision of the physician. The women were given the drugs freely to take home and the compliance of the women cannot be independently verified.

The prevalence of asymptomatic malaria in our study area is 44%. Variable prevalence of malaria ranging from low (7.7%),^[@R21]^ to high (75%)^[@R22]^ has been reported among pregnant women in Nigeria. Agomo *et al.*^[@R21]^ attributed these differences in the reported prevalence rates to the skill and experience of the laboratory personnel involved in blood film preparation, staining, and reading of the slides. In our study, we relied on PCR for the true prevalence of asymptomatic malaria in the study population. PCR-based assays remain the most sensitive and specific methods for the detection of malaria parasites.^[@R17]^

Although anemia was more common among pregnant women who had malaria parasite compared to those who did not, the difference was not significant. One explanation for this observation could be because most of the malaria positive pregnant women had low density and submicroscopic parasitemia. Thus, these parasites are unlikely to have contributed significantly to the presence of anemia in this study population.

In conclusion, we report a high prevalence of dhfr gene mutations in submicroscopic falciparum parasite obtained from pregnant women in Nigeria. Replacement of SP by an alternative drug will be necessary in the near future for successful implementation of IPTp. Regular assessment of sulfadoxine/pyrimethamine and its correlation to molecular markers in pregnant women is also recommended.
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